Drug Resistance to HIV-1 Integrase Inhibitors Among Treatment-Naive Patients in Beijing, China.
PMID: 35300056
2022
Pharmacogenomics and personalized medicine
Result: The most common non-nucleoside reverse transcriptase inhibitors (NNRTIs) associated mutation was V179D (4.97%, 43/865), followed by V179E (4.05%, 35/865) and V106I (2.89%, 25/865).
Pretreatment drug resistance in people living with HIV: A large retrospective cohort study in Chongqing, China.
Abstract: The predominant DRMs for non-nucleoside reverse transcriptase inhibitors (NNRTIs) and nucleoside reverse transcriptase inhibitors (NRTIs) were V179D/E/A/DIN (13.60%) and M184V/I (1.44%), respectively, whereas only two major DRMs (M46L and I54L) were identified for protease inhibitors (PIs).
High Level of Pre-Treatment HIV-1 Drug Resistance and Its Association with HLA Class I-Mediated Restriction in the Pumwani Sex Worker Cohort.
Discussion: Knowledge of the high level of K103R polymorphism in this study population is important if population levels of the V179D variant increase.
Discussion: When present with the variant V179D, which was not found in our participants, K103R can reduce susceptibility to NVP and EFV approximately 15-fold.
Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi-centre 48-week efficacy and safety study in Thailand.
PMID: 35001501
2022
Journal of the International AIDS Society
Method: We excluded individuals with prior evidence of NNRTI-associated resistance mutations based on the IAS-USA HIV drug-resistance mutations list (2019) (V90I, A98G, L100I, K101E/H/P/Q/R/N, K103N/S, V106A/M/I, V108I, E138K/A/G/Q/R, V179D/F/L/T, Y181C/I/V, Y188L/C/H, Result: Two other study participants developed the V179D mutation, which is not associated with reduced susceptibility to RPV on its own.
Phase 2 Open-Label Study of Long-Term Safety, Tolerability, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive Adolescents Living with HIV-1.
PMID: 34871089
2022
Antimicrobial agents and chemotherapy
Method: Patients with previously documented HIV-2 infection, with active AIDS, and with documented genotypic evidence of >=1 NNRTI resistance-associated mutation (RAM) from a predefined list of the following NNRTI RAMs at screening were excluded: A98G, L100I, K101E, K101P, K101Q, K103H, K103N, K103S, K103T, V106A, V106M, V108I, E138A, E138G,
Single Oral Doses of MK-8507, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Suppress HIV-1 RNA for a Week.
PMID: 34654041
2022
Journal of acquired immune deficiency syndromes (1999)
Result: The E138G and V179D variants were detected in 1 participant each in the 600 mg panel before dosing, but were not detected postdose.
Table: V179D
Discussion: Two NNRTI-resistance-associated variants (E138G and V179D) were detected in 1 participant each in the 600 mg panel before dosing, but were not detected postdose, indicating that MK-8507 did not select for these.
HIV Drug Resistance Mutations Detection by Next-Generation Sequencing during Antiretroviral Therapy Interruption in China.
Result: At baseline, mutations with a frequency of 20% and above were NRTI-related, such as M184VI (2.0%, 1/49), and NNRTI-related like K103N (14.3%, 7/49), E138AG (4.1%, 2/49), V179D (2.0%, 1/49) and P225H (2.0%, 1/49).
Result: The most common drug resistance mu
Discussion: Compared with the baseline, the HIVDR mutations, such as N88D, K65R, M184VI, K103N, E138AG, V179D and P225H, still existed but the frequency gradually decreased, consistent with earlier studies.
HIV-1 molecular transmission network among sexually transmitted populations in Liaoning Province, China.
Result: Among them, 9 cases were protease inhibitor-related resistance, and the main resistance sites were L33F, V82A, Q58E, M46L, M46I; There were 4 cases of nucleoside reverse transcriptase inhibitor resistance, the main mutation sites were V75VI, K219Q, T215A, K65R; There were 5 cases of non-nucleoside reverse transcriptase inhibitor resistance, the main mutation sites were V179E, A98G, V106I,
Table: V179D
Low Frequency of Integrase Inhibitor Resistance Mutations Among Therapy-Naive HIV Patients in Southeast China.
PMID: 33679129
2021
Drug design, development and therapy
Result: A total of 12 samples contained 13 NNRTIs-resistance mutations:V106I in 4 samples, V179E, V179D mutations each in 3 samples, E138A mutations in 2 samples and V106M in 1 sample.
Table: V179D
HIV-1 Drug Resistance and Genetic Transmission Networks Among MSM Failing Antiretroviral Therapy in South China 2014-2019.
HIV mutation literature information.
PMID: 
2022
Pharmacogenomics and personalized medicine
Browser Board
Co-occurred Entities
Filtrator
ViMRT